Dr. Dean Elterman is an Associate Professor of Urology at the University of Toronto, sub-specializing in functional urology.
As an attending urologist at the University Health Network (Toronto), his clinical and research interests include voiding dysfunction, novel technologies for BPH, sacral neuromodulation, male incontinence, and men’s health.
He trained at the University of Toronto, Memorial Sloan-Kettering Cancer Center and New York Presbyterian/Weill Cornell Medical College. He holds a Master’s degree in Clinical Epidemiology and Health Services Research from Cornell.
He is the Medical Director of the Sexual Health Clinic at Princess Margaret Cancer Center and Fellowship Director for functional urology. He is the recipient of the 2022 SIU Innovators award, leads numerous clinical trials in BPH and neuromodulation, and has published over 200 peer-reviewed manuscripts including the lead author of the Canadian guidelines for Male LUTS/BPH.
He is the Associate Editor of European Urology Focus. He is an Associate Member of the European Association of Urology Section of Endourology and the European Association of Urology Section of Functional Urology.
He is the Chief Medical Officer and Director for MedTechSyndicates.
Selected publications from PubMed
Clinical guidance and expert opinion on the use of prostatic urethral lift implants for benign prostatic hyperplasia.
Fields E, Al-Hasani HS, Polo J, Bhojani N, Elterman D, Chugthai B
Expert Rev Med Devices. 2026 Sep;23(9):991-997 doi: 10.1080/17434440.2026.2711873.
Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia.
Fields E, Elterman D, Bhojani N, Polo J, Chughtai B
Expert Opin Drug Metab Toxicol. 2026 Aug;22(8):633-649 doi: 10.1080/17425255.2026.2725917.
Navigating the New Landscape: A Clinical Commentary on the 2026 AUA Guideline on Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.
Elterman D, Bhojani N, Chughtai B
J Urol. 2026 Aug 20;:101097JU0000000000005269 doi: 10.1097/JU.0000000000005269.
Recalibrating sham-relative superiority thresholds in BPH device trials.
Polo J, Mugglin A, Bhojani N, Zorn K, Kaplan S, Elterman D, Chughtai B
World J Urol. 2026 Aug 13;44(1) pii: 559. doi: 10.1007/s00345-026-06645-1.
Diagnostic accuracy of intravesical prostatic protrusion (IPP) for bladder outlet obstruction using urodynamics as reference standard: a systematic review and meta-analysis.
Han Y, Yaghi MH, Polo J, Elsadany M, Elterman D, Bhojani N, Chughtai B
World J Urol. 2026 Aug 1;44(1) pii: 539. doi: 10.1007/s00345-026-06664-y.
BPH is a common condition that significantly impacts men’s quality of life, often manifesting as LUTS. While watchful waiting remains a conventional approach for many patients, delayed intervention can lead to progressive bladder dysfunction and diminished outcomes. The growing focus on early, evidence-based treatment emphasizes the importance of precise diagnostics and tailored therapies to balance timely intervention with optimal results. This webinar brings together leading experts to discuss how urodynamics and data-driven approaches are shaping the future of BPH management.
With Laborie
Published
Jan 2025
The less invasive Rezum treatment is, the higher the likelihood of meeting the patient's expectations regarding risks and benefits. That’s why performing less invasive Rezum treatments is recommended to achieve the greatest benefits when dealing with benign prostatic hyperplasia.
With Boston Scientific
Published
Nov 2021
Minimally Invasive treatment for BPH; Water steam generated by radiofrequency; Transmitted via convection throughout the targeted zone of the prostate over 9 seconds.
With Boston Scientific
Published
Jan 2020
Help your network discover Dr. Dean Elterman's clinical expertise.
